A core focus is the development of our own clinical-stage RNA therapeutics, having developed a broad pipeline of product candidates.

Our technology also serves as an important foundation for several external siRNA programmes currently in clinical development worldwide. We have partnerships and licenses with pharmaceutical companies around the world, demonstrating the significance of our RNA technology within the sector.


Out-licensed programmes (AtuRNAi)

Quark Pharmaceuticals inc. (‘Quark’) has licensed Silence’s AtuRNAi® for its PF-655 product, which has in turn been licensed to Pfizer. Phase 2 results are awaited in Diabetic Macular Edema.

Novartis has taken an option to licencse Quark’s QPI 1002, targeting Delayed Graft Function (DGF) in kidney transplant patients and Acute Kidney Injury(AKI).

In October 2015 Quark’s parent company SBI Holdings reported plans to begin patient dosing in Phase 3 dosing in DGF and in Phase 2 for AKI. Both of Quark’s drugs use naked siRNA.

Click here for information on our pre-clinical development programmes.